Listen

Add to my selection

OCREVUS

Medicine - Posted on Jun 12 2025

Active substance (DCI)

ocrelizumab

history (4)

5/14/25

OCREVUS (ocrelizumab) - Multiple sclerosis

Summary of opinion Favourable opinion for reimbursement in: the treatment of adult patients with early primary progressive m...

CAV :
54321

icône flèche
5/14/25

OCREVUS (ocrelizumab) - Multiple sclerosis (RMS)

Summary of opinion Favourable opinion for maintenance of reimbursement in the treatment of adult patients with relapsing for...

CAV :
54321

icône flèche
7/11/18

OCREVUS (ocrelizumab), immunosuppressant

Moderate clinical benefit in early-stage primary progressive multiple sclerosis (PP-MS) in terms of disease duration and deg...

CAV :
54321

icône flèche
5/30/18

OCREVUS (SEP récurrente)

OCREVUS (SEP récurrente)

CAV :
54321

icône flèche

Technical information

ATC code

L04AG08

Manufacturer

ROCHE SAS

Presentation

OCREVUS 300 mg, solution à diluer pour perfusion
1 flacon en verre de 10 mL (CIP : 34009 550 483 6 7)

OCREVUS 920 mg, solution injectable
1 flacon en verre de 23 mL (CIP : 34009 551 018 9 5)

All our publications

Autoimmune diseases

Central nervous system diseases

Demyelinating diseases